products

technologies

FluidCrystal® injection depot

FluidCrystal® injection depot

FluidCrystal® injection depot

Camurus' FluidCrystal® injection depot can deliver therapeutic levels of drug substance over extended periods - tunable from days to months - from a single injection. The system is suitable for delivery of e.g. potent peptides and small molecules and offers a ready-to-use design facilitating easy administration.

The FluidCrystal® injection depot consists of a liquid lipid solution which on contact with minute amounts of water in the body transforms to a liquid crystalline gel. The gel effectively encapsulates the drug compound and when the depot is biodegraded the compound is slowly and steadily released in the body.

The FluidCrystal® system does not suffer from the limitations of high initial drug release, limited chemical and physical stability, complicated reconstitution and administration as well as costly manufacturing often associated with traditional microparticle based depot technologies.

Liquid crystalline gels can effectively encapsule a broad spectrum of substances, and because structure formation begins immediately after injection the release is slow and steady in the body.
The liquid crystalline structure have a protective effect for many sensitive substances which is a reason behind the high bioavilability that has been documented for the FluidCrystal® system.
The low viscosity in Camurus’ depot formulation makes the products based on the FluidCrystal® system easier to handle, easier to inject with fine needle and easier to manufacture, compared to conventional microparticle based depot.

The FluidCrystal® depot products are easily and conveniently administered in small doses by injection with a pre-filled standard syringe with a thin needle. The technology can also be complemented with a needle stick prevention device or an auto-injector. Camurus’ depot technologies make life easier for both patients and healthcare professionals. Products based on this technology are also well-suited for home-based administration by the patient or family members.


Key properties

  • Slow and steady release
  • Tunable release from days to months
  • Ready-to-use product design
  • Small injection through thin needles
  • Compatible with standard prefilled syringes and injection aids (e.g. autoinjectors)
  • Good local tolerability demonstrated in clinical and preclinical trials
  • Good systemic safety demonstrated in clinical and preclinical trials
  • Room temperature storage
  • Simple and standard manufacturing process


  1. Subcutaneous injection of lipid based formulation
  2. Liquid crystal gel formation on water absorption (w)
  3. Slow release of drug compound (D), biodegradation of depot



FluidCrystal® topical bioadhesive

FluidCrystal® topical bioadhesive

FluidCrystal® topical bioadhesive

Camurus' FluidCrystal® topical bioadhesive delivery technology is applied on topical surfaces where it spreads to form a thin bioadhesive film which protects the biosurface and can be used to locally release active drug substances. The system is suitable for prolonged local release of e.g. peptides and small molecules on oral, nasal, vaginal and rectal mucosa as well as on the skin.

The formulation is applied as a low viscous liquid to topical surfaces, where it spreads to form a thin bioadhesive film after absorption of minute amounts of water. The nanostructure of the film can be tuned for optimum release and bioadhesive characteristics. The formulation has a high solubilising capacity, which allows small dosage volumes to achieve therapeutic effects with the active ingredient.
FluidCrystal® topical bioadhesive is compatible with several applicators, such as disposable pipettes, tubes and spray bottles.

The commercially available product episil® is based on the FluidCrystal® topical delivery system.

Key properties

  • Strongly bioadhesive
  • Protects sensitive biosurfaces
  • Relieves local pain
  • High solubilising capacity for drug compounds
  • Extended local drug release
  • High local tolerance demonstrated in clinical trials
  • Simple and standard manufacturing process



FluidCrystal® nanoparticles

FluidCrystal® nanoparticles

FluidCrystal® nanoparticles

FluidCrystal® nanoparticles addresses bioavailability limitations for amphiphilic and lipophilic drugs or biodegradation sensitive drugs.

FluidCrystal® nanoparticles are usually water-based and comprise a stable emulsion of nanoparticles with a liquid crystalline structure. The technology has been designed to increase the bioavailability of amphiphilic and lipophilic drugs with low aqueous solubility and biodegradation-sensitive drugs such as peptides and proteins.
Products based on this technology are either preformed to stable dispersions for intravenous, subcutaneous, intramuscular or intracavital injection, or applied to the skin or mucous membranes in spray form.

Key properties

  • Prolonged systemic circulation (parenteral administration)
  • Enhanced delivery over mucosal and skin surfaces (topical administration)
  • Encapsulation of sensitive drugs
  • High drug payloads
  • Besed on safe excipients
  • Good systemic and local tolerability




UP

Important information

The information contained in this section of Camurus AB’s (the "Company") website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Canada, Japan, Australia, New Zealand, South Africa, Hong Kong, Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Canada, Japan, Australia, New Zealand, South Africa, Hong Kong, Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction. Any securities of the Company referred to on this website (the "Securities") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Securities have also not been and will also not be registered under the applicable securities laws of Canada, Japan, Australia, New Zealand, South Africa, Hong Kong or Singapore and, subject to certain exemptions, may not be offered or sold in or into or for the account or benefit of any person having a registered address in, or located or resident in, Canada, Japan, Australia, New Zealand, South Africa, Hong Kong or Singapore. There will be no public offer of the Shares in Canada, Japan, Australia, New Zealand, South Africa, Hong Kong or Singapore. Access to the information and documents contained on the following websites may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person